Eisai’s Dacogen Final Results On Overall Survival Get Preliminary Test At Advisory Committee

Preliminary evidence from the pivotal trial of decitabine for acute myelogenous leukemia showed the increase in overall survival wasn’t statistically significant, but final results show a benefit of more than 50% compared with the control arm.